Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care ...

With a mix of breakout sessions, hands-on workshops, and in-depth discussions, learning from real-world case studies that ...

CRUK has invested more than £43 million into the RadNet programme since it was launched in 2019, and Manchester is one of ...

Watertown, Massachusetts-based Disc has agreed with the FDA that it will use average monthly time in sunlight during the last ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...